Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.
Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...
Swiss pharma heavyweight Novartis is cutting a very large check. The company has agreed to acquire London-headquartered ...
Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis ...
Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...
Ascletis submits two IND applications to the US FDA to treat obesity: ASC36 once-monthly injection & ASC36_35 FDC once-monthly injection: Hong Kong Tuesday, July 7, 2026, 12:00 Hr ...
PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class ...
Novartis AG NVS has agreed to acquire privately held U.K. biotechnology company Myricx Bio in a deal valued at up to $1.5 ...
Investor's Business Daily on MSN
Why this biotech, up 12% since its breakout, yo-yoed on a key FDA development
Pharvaris stock jumped early Monday, but closed down, after the FDA agreed to review the company's treatment for a serious ...
Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results